DaShenLin Pharmaceutical Group Co., Ltd. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported sales was CNY 25,860.98 million compared to CNY 23,931.45 million a year ago. Revenue was CNY 26,496.55 million compared to CNY 24,531.39 million a year ago.
Net income was CNY 914.75 million compared to CNY 1,166.5 million a year ago. Basic earnings per share from continuing operations was CNY 0.81 compared to CNY 1.03 a year ago. Diluted earnings per share from continuing operations was CNY 0.81 compared to CNY 1.03 a year ago.
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company is mainly engaged in the chain retail business of Chinese and Western patent medicines, ginseng and antler tonic medicinal materials and Chinese herbal medicine slices, health products, medical devices and other commodities. The Company is also involved in the production of Chinese herbal medicine slices, ginseng and antler tonic, health products, Chinese and Western patent medicines. The Company's brands include Dong Zi Yun Xuan, Cocoking, Nobe Huale, Dongteng Ejiao, and Fuer. The Company mainly conducts business within domestic market.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.